Melanotan II: 33 Subjects, Zero Approvals, and a TikTok Boom

Melanotan II (MT-II, CAS 121062-08-6) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a molecular weight of 1,024.2 Da. It was developed at the University of Arizona in the late 1980s by a research team led by Victor J. Hruby (professor emeritus of chemistry) and the late Mac E. Hadley (professor emeritus of anatomy), along with Robert T. Dorr and Norman Levine. The team had been studying melanocortin hormone chemistry since 1969.

The original research goal was cancer prevention, not cosmetic tanning. The hypothesis was straightforward: if a compound could stimulate melanin production without ultraviolet exposure, people could develop a protective tan that would shield them from solar radiation damage. The body’s natural tanning hormone, alpha-MSH, degrades within minutes in the bloodstream, making it impractical as a therapeutic agent. After synthesising and screening hundreds of molecules, the Arizona team created a cyclic (ring-shaped) structure designated [Nle4, D-Phe7]-alpha-MSH that was approximately 1,000 times more potent than natural alpha-MSH and resistant to enzymatic degradation.

This compound became Melanotan II. Its cyclic structure has no exposed chain ends for enzymes to attack, giving it a substantially longer biological half-life than the linear alpha-MSH. However, the potency came at a cost: while the natural hormone primarily activates MC1R (the pigmentation receptor), Melanotan II is a non-selective agonist that activates MC1R, MC3R, MC4R, and MC5R with no significant MC2R binding. This broad receptor activation produces melanogenesis (tanning) through MC1R, but also sexual arousal through MC3R/MC4R, appetite suppression through MC4R, and other systemic effects – none of which were part of the original cancer-prevention design.

The bottom line: Melanotan II was designed to prevent skin cancer by stimulating melanin, but its non-selective receptor activation produces a range of unintended systemic effects, and it has never completed the clinical testing required for approval anywhere in the world.

Melanotan II binds to melanocortin receptors on cell surfaces. Five types of melanocortin receptors exist (MC1R through MC5R), and MT-II activates several of them simultaneously, each triggering a different biological response.

Melanogenesis (Tanning)

When MT-II binds to MC1R on melanocytes (the pigment-producing cells in skin), it activates the cAMP-PKA signalling pathway. This triggers melanogenesis – the production of melanin pigment, specifically eumelanin, which provides the brown coloration associated with tanning. Unlike UV-induced tanning, this process can occur without sun exposure, though many users combine MT-II with UV to accelerate results. The tanning effect is genuine and pharmacologically well-understood.

Sexual Arousal

MC3R and MC4R activation in the hypothalamus triggers the same central arousal pathways exploited by PT-141 (bremelanotide), the FDA-approved derivative of Melanotan II. In the Wessells et al. studies (1998, 2000) at the University of Arizona, subcutaneous MT-II induced erections in 17 of 20 men with erectile dysfunction in a double-blind crossover design – but also produced dose-dependent priapism (prolonged, painful erections lasting 1 to 5 hours), which is a medical emergency.

Appetite Suppression

MC4R activation in brain regions governing energy balance produces appetite reduction and weight loss. This effect is real and has contributed to the compound’s appeal beyond tanning, particularly on social media. However, MC4R-mediated appetite suppression through a non-selective agonist carries systemic risks that selective MC4R agonists (like setmelanotide, which is FDA-approved for rare genetic obesity conditions) were specifically designed to avoid.

The bottom line: Melanotan II genuinely produces tanning, sexual arousal, and appetite suppression, but its non-selective receptor activation means every desired effect comes bundled with every undesired effect.

The entire controlled human evidence base for Melanotan II consists of one Phase I tanning study and two small erectile dysfunction studies. No Phase II or Phase III trials have ever been conducted.

Study	Population	Design	Key Finding	Evidence Tier
Dorr et al. 1996 (Life Sciences)	3 healthy volunteers	Phase I, dose-escalation	Significant tanning after 5 doses; nausea at every dose level	Phase I (3 subjects)
Wessells et al. 1998	10 men, ED	Double-blind crossover	Dose-dependent erectile response; priapism events (1-5 hours)	Phase I/II (10 subjects)
Wessells et al. 2000	20 men, ED	Double-blind crossover	Erections in 17/20 without sexual stimulation	Phase I/II (20 subjects)
Hjuler & Lorentzen 2014 (Dermatology)	1 woman, age 20	Case report	Melanoma during MT-II + sunbed use	Case report
Habbema et al. 2017 (Int J Dermatol)	Literature review	Safety review	Four melanomas from existing moles during/after MT-II use; dysplastic nevi	Systematic case review
Nelson et al. 2012 (Clinical Toxicology)	1 man, age 39	Case report	Rhabdomyolysis (CPK 17,773 IU/L), tachycardia 146 bpm, acute kidney injury from single 6 mg injection	Case report
Peters et al. 2020 (CEN Case Reports)	1 man, previously normotensive	Case report	Hypertension (165/95 mmHg), right-sided renal infarction after 6 months of use	Case report

This is not a technicality. The dose-response relationship, long-term safety profile, and population-level risk of Melanotan II in humans are fundamentally unknown because the compound was never tested at a scale that could characterise them. Every claim about MT-II’s safety – positive or negative – is extrapolated from 33 total controlled human exposures and a collection of individual adverse event case reports.

The bottom line: Melanotan II has Phase I data in 33 total subjects and has never undergone the large-scale safety and efficacy testing required for regulatory approval in any country.

The relationship between Melanotan II and melanoma is the most serious unresolved safety question surrounding this compound, and the evidence is more nuanced than either promotion or prohibition narratives suggest.

Melanotan II’s potent MC1R stimulation causes existing moles (nevi) and freckles to darken rapidly. The Habbema 2017 review in the International Journal of Dermatology compiled dermatological complications reported across the literature, documenting darkening of existing moles, rapid appearance of new nevi including dysplastic nevi (which are melanoma precursors), and changes in the size and shape of pre-existing melanocytic lesions. Four case reports in the peer-reviewed literature describe melanomas emerging from existing moles during or shortly after Melanotan II use.

A 2013 scientific review (Javed et al.) found no conclusive causal evidence that MT-II causes melanoma. A 2021 review (Wensink et al.) concluded that the increased melanoma risk observed in Melanotan users could probably be explained by greater UV exposure, since MT-II users frequently combine the compound with sunbed use or sun exposure to accelerate tanning. A 2020 in-vivo study found that Melanotan II actually suppressed melanoma progression in mice – suggesting the relationship between melanocyte stimulation and melanoma is not straightforward.

What is not debatable: MT-II causes clinically significant changes in melanocytic lesions that complicate skin cancer surveillance. The UK’s MHRA and Australia’s TGA have both issued formal safety warnings citing melanoma risk specifically, and dermatologists recommend that any person who has used Melanotan II undergo a baseline full-body skin examination with regular follow-up and mole photography.

The bottom line: Whether Melanotan II directly causes melanoma remains scientifically unresolved, but it unquestionably produces melanocytic changes that obscure melanoma detection and are biologically plausible risk factors.

Melanotan II has attracted more active regulatory enforcement than almost any other unapproved peptide. Unlike compounds that exist in regulatory grey areas, MT-II has been the subject of direct warnings, website shutdowns, seizures, and financial penalties.

Jurisdiction	Status	Enforcement Actions
United States (FDA)	Unapproved New Drug	Multiple warning letters to companies marketing MT-II for tanning. Products marketed for human use are unapproved new drugs and misbranded. Not on the 503A Category 1 or Category 2 lists.
United Kingdom (MHRA)	Unlicensed Medicine	72 websites shut down. 18 Yellow Card reports totalling 74 suspected adverse reactions (stomach and heart problems). Classified as medicinal product requiring marketing authorisation under the Human Medicines Regulations 2012.
Australia (TGA)	Schedule 4 / Not on ARTG	27 infringement notices totalling $101,412 issued to NSW-based individual (paid May 2026). Public safety warning issued 2025. Customs seizures of imported products. Classified as prescription-only medicine but not approved for sale as tanning agent. Illegal to supply or advertise to the public.
European Union (EMA)	Not Approved	EMA warnings issued. Enforcement varies by member state. Generally treated as unapproved medicinal product.
WADA	Prohibited	Prohibited under S2 (peptide hormones and mimetics) and additionally captured under S0 (non-approved substances) as an unapproved drug with no therapeutic use exemption pathway.

For broader context on peptide legality by country, see our guides on US, UK, and Australian peptide legality, and our explanation of the FDA category system.

The bottom line: Melanotan II is actively enforced against in all major markets, with the Australian TGA levying over $100,000 in fines in 2026 and the MHRA shutting down 72 UK-facing supply websites.

Melanotan II will not be approved for any indication in any major market. This is not a matter of regulatory delay – it is a structural impossibility driven by three converging factors.

First, the compound is off-patent. With no intellectual property protection, no pharmaceutical company can recoup the estimated $500 million to $1 billion cost of conducting Phase II/III trials and filing a New Drug Application. Without a commercial sponsor, there is no funding pathway for the clinical development required for approval.

Second, every medically useful effect of Melanotan II has been captured by selective successors that are already approved or in advanced development. MC1R-selective tanning and photoprotection is covered by afamelanotide (Scenesse). MC3R/MC4R-selective sexual dysfunction is covered by bremelanotide (Vyleesi). MC4R-selective appetite/obesity is covered by setmelanotide (Imcivree). There is no clinical gap that only Melanotan II’s non-selective receptor activation can fill.

Third, the safety profile of a non-selective melanocortin agonist in a cosmetic tanning indication would be extremely difficult to justify to regulators. Cosmetic products face a higher benefit-risk scrutiny because the condition being treated is not medically serious. The melanoma-related dermatological changes, priapism risk, cardiovascular events, and rhabdomyolysis case reports would make regulatory approval of MT-II as a tanning agent essentially impossible, even if the clinical trials were funded.

Public health researchers classify Melanotan II not as a cosmetic product but as an image and performance-enhancing drug (IPED) – the same category applied to anabolic steroids, human growth hormone, and synthol. This classification matters because it shifts the analytical framework from consumer product safety to substance use epidemiology, where the relevant questions involve prevalence among vulnerable populations, injection risk behaviour, and patterns of poly-drug use.

The Needle Exchange Signal

The first systematic documentation of widespread unregulated Melanotan use came not from dermatology clinics but from UK needle and syringe programmes. Evans-Brown et al. published a landmark report in the BMJ (2009;338:b566) after multiple needle exchange workers contacted the Centre for Public Health at Liverpool John Moores University seeking information about “melanotan” – their clients were presenting alongside anabolic steroid users to obtain injection equipment. The Evans-Brown report flagged that the demand for synthetic melanocortin analogues was crossing from bodybuilding subcultures into the general population, driven by the dual appeal of tanning and sexual enhancement.

Subsequent research by the same group (Evans-Brown et al. BMJ Open 2013;3:e003207) examined the prevalence of HIV, hepatitis B, and hepatitis C among men who inject image and performance-enhancing drugs. The findings were significant: IPED injectors – including Melanotan users – demonstrated elevated rates of blood-borne virus exposure linked to needle sharing, multi-vial sharing, and non-sterile injection technique. Unlike heroin or methamphetamine injectors, IPED users frequently have no prior injection experience and no contact with harm reduction services. Many do not perceive themselves as “drug users” and are therefore unreachable through conventional substance use outreach.

Qualitative Evidence: What Users Actually Report

A 2021 qualitative study published in Dermatology (Karger, 237(6):995) analysed online discussion forum content from Melanotan II users, documenting the gap between marketed safety claims and real-world user experience. The study found several consistent patterns: users commonly reported self-titrating doses based on anecdotal internet guidance rather than clinical data; most experienced nausea and mole changes but interpreted them as expected rather than concerning; and many continued use despite side effects because the tanning results were rapid and dramatic. The study also documented rationalisation behaviour – users comparing MT-II favourably to sunbed use, arguing that both carry skin cancer risk but MT-II provides better cosmetic results. This framing treats the absence of evidence (no long-term MT-II cancer data) as evidence of absence (MT-II is no worse than sunbeds).

The bottom line: Public health researchers treat Melanotan II as an image-enhancing drug that introduces injection practice to populations with no prior needle exposure, creating blood-borne virus risk alongside the compound’s direct pharmacological harms.

The safety profile of Melanotan II is characterised by high-frequency acute side effects and rare but serious adverse events, with an additional layer of risk from unregulated manufacturing and contamination.

Common Side Effects

• Nausea – reported at every dose level in the only Phase I trial (100% incidence). Most common in the first 1-2 weeks of use.
• Facial flushing – common, typically resolves within hours.
• Appetite suppression – consistent with MC4R activation, sometimes severe.
• Fatigue and yawning – frequently reported in community use.
• Mole darkening and new mole formation – pharmacologically expected from MC1R activation on melanocytes.
• Spontaneous erections in men – from MC3R/MC4R activation, potentially progressing to priapism.

Serious Adverse Events (Case Reports)

• Rhabdomyolysis – Nelson et al. (2012, Clinical Toxicology): a 39-year-old man developed CPK levels of 17,773 IU/L, tachycardia of 146 bpm, and acute kidney injury after a single 6 mg injection.
• Renal infarction – Peters et al. (2020, CEN Case Reports): a previously normotensive man developed hypertension (165/95 mmHg) and CT-confirmed right-sided renal infarction after 6 months of subcutaneous use.
• Melanoma – four case reports in the peer-reviewed literature describe melanomas emerging during or shortly after MT-II use (Habbema 2017 review). An oral mucosal malignant melanoma was reported in a 22-year-old woman after nasal spray use (Yassin 2025).
• Melanonychia – brown to black discolouration of nails, potentially permanent.
• Priapism – documented in the Wessells studies (erections lasting 1-5 hours), which constitutes a urological emergency.

Product Quality Risks

Because Melanotan II is manufactured exclusively by unregulated suppliers, there is no guarantee of identity, purity, sterility, or dose accuracy in any product sold online. Products labelled as MT-II may contain incorrect peptides, bacterial endotoxins, heavy metals, or degradation products. The “research chemical” label is a legal boundary, not a quality assurance. For guidance on evaluating peptide quality documentation, see our guide on how to read a certificate of analysis.

The bottom line: Melanotan II produces nausea in virtually all users, causes melanocytic changes that complicate cancer screening, and has documented case reports of rhabdomyolysis, renal infarction, and melanoma – all in the context of products manufactured without regulatory oversight.

Melanotan II is the common ancestor of two FDA-approved drugs, both of which were specifically engineered to isolate one of MT-II’s effects while eliminating the others.

Afamelanotide (also called Melanotan I, branded as Scenesse) is a linear 13-amino-acid peptide that selectively activates MC1R for melanogenesis. It was licensed by Competitive Technologies (the University of Arizona’s technology transfer partner) to an Australian startup called Epitan, which later became Clinuvel Pharmaceuticals. The EMA approved Scenesse for EPP in 2014, and the FDA followed in October 2019. Afamelanotide is delivered as a 16 mg subcutaneous implant every two months and is available only through a restricted distribution programme for patients with a confirmed EPP diagnosis.

Bremelanotide (PT-141), marketed as Vyleesi, was developed by Palatin Technologies from Melanotan II to isolate the sexual dysfunction activity. Palatin ceased development of Melanotan II itself in 2000, synthesised bremelanotide as a metabolite differing by a carboxy group where MT-II has an amide, and patented it as a distinct compound. A contract dispute with Competitive Technologies over bremelanotide ownership was settled in 2008, with Palatin retaining bremelanotide rights, returning Melanotan II rights, and paying US$800,000.

Feature	Melanotan II	Afamelanotide (Scenesse)	Bremelanotide (Vyleesi)
Structure	Cyclic heptapeptide	Linear tridecapeptide (13 AA)	Cyclic heptapeptide (MT-II metabolite)
Receptor Profile	Non-selective (MC1R/3R/4R/5R)	MC1R-selective	MC3R/MC4R-biased
Primary Effect	Tanning + sexual + appetite	Melanogenesis / photoprotection	Sexual desire / arousal
FDA Status	Not approved	Approved (EPP, Oct 2019)	Approved (HSDD, Jun 2019)
Clinical Stage Reached	Phase I only	Phase III (approval)	Phase III (approval)
Manufacturer	Unregulated suppliers only	Clinuvel Pharmaceuticals	Cosette Pharmaceuticals
Melanoma Concern	Case reports + TGA/MHRA warnings	Nevi monitoring required per label	Focal hyperpigmentation (rare)

The bottom line: Every clinically useful melanocortin effect has been captured by approved receptor-selective successors; Melanotan II’s only differentiator is that it produces all effects simultaneously in an uncontrolled, untested manner.

Melanotan II has experienced a resurgence of interest driven by TikTok and Instagram promotion, particularly through tanning nasal sprays marketed to young adults. Dubbed the “Barbie drug,” MT-II is promoted by influencers who emphasise rapid tanning while downplaying or ignoring the safety profile. The TGA has noted that these advertising rules apply to anyone disseminating information about therapeutic goods, including influencers and all media types visible to the public, and has worked with social media platforms to remove unlawful advertisements.

The tanning nasal spray format is particularly concerning because it gives the impression of a cosmetic product rather than an injectable peptide, potentially lowering the perceived risk threshold for new users. The TGA’s 2025 public warning explicitly noted that promoters often claim these products are “safe and natural” when they are “far from safe.”

However, the social media surge is not the first wave of public demand for Melanotan. The Danish Health and Medicines Authority issued a consumer warning against Melanotan products as early as August 2008 – more than a decade before TikTok existed. The MHRA first described MT-II as “an unlicensed medicine” and shut down supply websites in 2008-2009, and Cousen et al. published the first case report of eruptive melanocytic naevi following melanotan injection in the British Journal of Dermatology that same year. What TikTok has done is not create demand for MT-II but amplify an existing underground market to a younger, less informed demographic who may never encounter the safety literature.

The Counterintuitive Finding: MT-II and Melanoma Suppression

One finding that complicates the melanoma narrative warrants mention for completeness: a 2020 in-vivo study found that Melanotan II suppressed the progression of melanoma in mice. This result is counterintuitive given the melanocyte-stimulation concern, and it is consistent with the original research hypothesis that drove MT-II’s development – that melanin itself provides photoprotective effects that reduce DNA damage. The finding does not resolve the safety question in humans (mouse models of melanoma do not reliably predict human outcomes), but it demonstrates that the relationship between melanocyte stimulation and melanoma is not the simple “more stimulation equals more cancer” narrative that either side of the debate often presents. The actual risk, if any, likely depends on the interaction between MT-II’s melanocyte activation, the user’s underlying genetic risk, UV co-exposure, and duration of use – variables that only controlled human trials could disentangle, and which will never be run.